Your search for hydroxyurea returned 48 results

Majority of youth in Michigan and New York with sickle cell anemia did not have filled hydroxyurea prescriptions.

Children with sickle cell disease had improved lung function after treatment with hydroxyurea, according to a study presented at the American Thoracic Society (ATS) 2016 International Conference.

Only 23 percent using the drug within a year of their last pain crisis

A clinical trial of hydroxyurea therapy for children with sickle cell anemia has been halted a year early because the results show it is a safe and effective way to manage the disease and reduce the risk of stroke.

Treating children with sickle cell anemia with hydroxyurea is associated with lower total medical costs (higher outpatient costs but lower inpatient costs) as compared to placebo.

In patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea, use of the JAK1/JAK2 inhibitor, INCB018424, results in rapid and durable clinical benefits, including normalization of hematologic parameters, resolution of splenomegaly, and alleviation of symptoms, long-term follow-up data from an ongoing open-label phase 2 study have found. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of July. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

Hydroxyurea 500mg; caps.

Hydroxyurea 200mg, 300mg, 400mg; caps.

Hydroxyurea used by 24.6 percent with sickle cell disease, while l-glutamine, voxelotor, crizanlizumab were used by 2.0, 1.9, and 1.4 percent